Cargando…

Gap Junction Enhancer Increases Efficacy of Cisplatin to Attenuate Mammary Tumor Growth

Cisplatin treatment has an overall 19% response rate in animal models with malignant tumors. Increasing gap junction activity in tumor cells provides the targets to enhance antineoplastic therapies. Previously, a new class of substituted quinolines (PQs) acts as gap junction enhancer, ability to inc...

Descripción completa

Detalles Bibliográficos
Autores principales: Shishido, Stephanie N., Nguyen, Thu A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441663/
https://www.ncbi.nlm.nih.gov/pubmed/23028705
http://dx.doi.org/10.1371/journal.pone.0044963